Spero Therapeutics (SPRO) Stock Forecast & Price Target

Spero Therapeutics is attractive fundamentally because SP001 offers a differentiated, Fc-silent anti-CD40L mechanism that targets upstream B- and T-cell signaling, potentially addressing IgG4-related disease more completely than B-cell depletion approaches while avoiding the thromboembolic issues seen with earlier CD40L antibodies. The thesis is strengthened by encouraging Phase 1b data in Sjögren’s disease showing tolerability, low immunogenicity, and meaningful reductions in disease activity, alongside a Phase 2 study expected in 2Q27 and a broader addressable market across inflammatory conditions. Financially, the company secured a $35M upfront license payment and a $105M royalty financing, with modeled valuation around $367M to $400M and runway into 2H29, while the SEC investigation was concluded without action.

Spero Therapeutics is facing a fundamentally कमजोर risk profile because its 2024 interim analysis showed the Phase 2a proof-of-concept study of SPR720 did not meet its primary endpoint, forcing significant restructuring to extend cash runway into mid-2026. That setback underscores a high probability of clinical-development failure, while the company’s broader pipeline remains exposed to stringent FDA and other regulatory requirements, any small safety signal, and the possibility that adverse efficacy or safety data could block approval. It also faces commercial pressure from competing programs and a likely need for new partnerships or financings, which could dilute value and limit flexibility before any product can generate meaningful revenue.